Exabis Library
Welcome to the e-CCO Library!
P422: Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assay
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P422: Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P422: Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P423 NF-kB as a prognostic marker of response to biologic therapy in children with IBD
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P423: Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P423: Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P423: Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P423: Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCU
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P423: Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P423: Treatment escalation and associated cost in German Ulcerative Colitis patients treated with advanced therapies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P424: Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P424: Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P424: Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUST
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P424: Surgery for children with Crohn’s disease.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P424: Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 years
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P424: Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM